Administrative Core
行政核心
基本信息
- 批准号:10709228
- 负责人:
- 金额:$ 26.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AdministratorAdvocateBasic ScienceBioinformaticsBiostatistics CoreCancer CenterClinicalClinical TrialsCollaborationsCommunicationDevelopmentDisciplineDisputesEnsureEvaluationGoalsInstitutionMalignant neoplasm of ovaryMentorshipMonitorOutcomeOvarianPathologyPatientsPoliciesPolicy ComplianceProceduresProcessQuality ControlRegulationReportingResearchResearch PersonnelResolutionTranslatingUnderrepresented MinorityUniversity of Texas M D Anderson Cancer CenterWomananticancer researchcareerdata qualitydata sharingimprovedinter-institutionalinterdisciplinary approachprogramsquality assurancerecruitsuccesstimeline
项目摘要
Core A: Administrative Core SUMMARY/ ABSTRACT
The overall goal of the MD Anderson Cancer Center SPORE in Ovarian Cancer is to translate high-quality research
into improved clinical outcomes for women with ovarian cancer. To ensure the success of the SPORE, the
Administrative Core will provide effective management and administration of all activities relating to each project,
core, career enhancement and developmental program in the SPORE. The Administrative Core will communicate
and disseminate information between our SPORE investigators and facilitate information sharing and collaborations
with other SPOREs and external collaborators. The Core will provide a platform for integrating diverse scientific
disciplines into a unified multidisciplinary approach for achieving excellence in translational ovarian cancer
research. The Administrative Core will monitor timelines and ensure both basic science and clinical trial aims are
met for all SPORE projects. Co-Core Directors and MPIs, Drs. Anil Sood and Robert Bast, along with Ovarian
SPORE Administrator, Ms. Ersulan Hampton and Ovarian SPORE Scientific Writer, Dr. Robert Langley, will direct
the objectives of the Administrative Core. The objectives of the Core are to: 1) direct the planning and evaluation to
ensure the overall scientific quality and strategic direction of the SPORE; 2) manage all fiscal and budgetary issues
across all Projects, Cores and Developmental Research and Career Enhancement Programs; 3) monitor the data
sharing compliance of the SPORE to adhere to all general governmental and specific NCI regulations and
requirements; 4) coordinate quality assurance activities, including data quality controls with support from the
Bioinformatics and Biostatistics Core and the Pathology Core; 5) serve as the communication hub for the SPORE
to provide up-to-date operating information to investigators; 6) communicate and confer with the NCI Project Officer
and other staff to make certain all necessary reporting requirements are met, including PMCID policy compliance;
7) coordinate the annual process for selection of Developmental Research and Career Enhancement Program
recipients, and establish policies and procedures that result in the successful recruitment of women and
underrepresented minorities to these programs and ensure awardees are supported with outstanding mentorship;
8) ensure the SPORE is integrated in administrative organization of the institution; 9) initiate and coordinate inter-
SPORE and inter-institutional interactions and seminars; 10) facilitate resolution of scientific disputes; and 11)
organize and maintain patient advocate involvement in the SPORE.
核心A:行政核心摘要/摘要
MD安德森癌症中心卵巢癌SPORE的总体目标是将高质量的研究成果转化为
改善卵巢癌患者的临床结果。为了确保SPORE的成功,
行政核心将为与每个项目有关的所有活动提供有效的管理和行政,
核心,职业提升和发展计划的SPORE。行政核心将沟通
并在我们的SPORE调查人员之间传播信息,促进信息共享和合作
与其他SPORE和外部合作者。核心将提供一个平台,
将多学科整合为统一的多学科方法,以实现转化性卵巢癌的卓越治疗
research.行政核心将监测时间表,并确保基础科学和临床试验目标
为所有的SPORE项目。联合核心董事和MPI,Anil Sood博士和Robert Bast博士,沿着卵巢癌
孢子管理员Ersulan汉普顿女士和卵巢孢子科学作家Robert兰利博士将指导
行政核心的目标。核心的目标是:1)指导规划和评价,
确保整个战略研究和环境研究的科学质量和战略方向; 2)管理所有的财政和预算问题
所有项目、核心和发展研究以及职业发展计划; 3)监控数据
共享SPORE的合规性,以遵守所有一般政府和特定NCI法规,
要求; 4)协调质量保证活动,包括在
生物信息学和生物统计学核心和病理学核心; 5)作为SPORE的通信枢纽
向调查人员提供最新的操作信息; 6)与NCI项目官员沟通和协商
和其他员工,以确保所有必要的报告要求得到满足,包括PMCID政策合规性;
7)协调发展研究和职业发展计划的年度遴选过程
(c)确保妇女和女童的就业机会,并制定政策和程序,成功征聘妇女,
代表性不足的少数民族参加这些计划,并确保获奖者得到出色的指导;
8)确保SPORE融入机构的行政组织; 9)发起和协调内部
SPORE和机构间互动和研讨会; 10)促进科学争议的解决;和11)
组织并保持患者倡导者参与SPORE。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANIL K SOOD其他文献
ANIL K SOOD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANIL K SOOD', 18)}}的其他基金
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
- 批准号:
9754614 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
- 批准号:
9979631 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
- 批准号:
9388779 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
Harnessing the power of exosomes for non-coding RNA delivery
利用外泌体的力量进行非编码 RNA 递送
- 批准号:
10670211 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
项目3:巨噬细胞在卵巢癌抗VEGF药物耐药中的作用
- 批准号:
10005297 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer
项目3:巨噬细胞在卵巢癌抗VEGF药物耐药中的作用
- 批准号:
10251116 - 财政年份:2017
- 资助金额:
$ 26.06万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 26.06万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 26.06万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 26.06万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 26.06万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 26.06万 - 项目类别: